BMS' Bid For Opdivo In First-Line HCC Stymied
Top-line results from a Phase III study testing Opdivo versus Nexavar in first-line liver cancer fail to meet OS target. Bristol points to positive numerical trend, but the results are a setback in the indication.
You may also be interested in...
Following quickly on a Bristol trial failure with Opdivo in first-line HCC, Roche’s PD-L1 inhibitor looks poised to be the first immunotherapy approved in the setting, with plans for US, EU and China filings.
The Checkmate-227 results surprised with an OS benefit for Opdivo plus Yervoy in first-line NSCLC and a miss for the Opdivo-chemotherapy combination. Bristol reported a solid quarter, with growth for IO, Eliquis.
Bristol-Myers will have to divest Celgene's blockbuster psoriasis pill to address concerns raised by the US FTC related to the merger. The news raised questions about whether FTC is giving more scrutiny to pipeline overlap.